Last reviewed 2026-04-20 · How we verify

methylorednisolone

Tehran University of Medical Sciences · FDA-approved active Small molecule Quality 1/100

methylorednisolone is a Small molecule drug developed by Tehran University of Medical Sciences. It is currently FDA-approved.

At a glance

Generic name	methylorednisolone
Sponsor	Tehran University of Medical Sciences
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

methylorednisolone CI brief — competitive landscape report
methylorednisolone updates RSS · CI watch RSS
Tehran University of Medical Sciences portfolio CI

Frequently asked questions about methylorednisolone

What is methylorednisolone?

methylorednisolone is a Small molecule drug developed by Tehran University of Medical Sciences.

Who makes methylorednisolone?

methylorednisolone is developed and marketed by Tehran University of Medical Sciences (see full Tehran University of Medical Sciences pipeline at /company/tehran-university-of-medical-sciences).

What development phase is methylorednisolone in?

methylorednisolone is FDA-approved (marketed).

Manufacturer: Tehran University of Medical Sciences — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing